VOLUME 6 , ISSUE 1 ( January-June, 2019 ) > List of Articles
Manjeet Singh, Ashwani Ummat, Chetan Sharma, Praveen S Thivari, Sonia Kochhar
Keywords : Chronic plantar fasciitis, Corticosteroid, Platelet-rich plasma
Citation Information : Singh M, Ummat A, Sharma C, Thivari PS, Kochhar S. Efficacy of Platelet-rich Plasma vs Corticosteroid Injection in Chronic Plantar Fasciitis: A Comparative Study. J Foot Ankle Surg Asia-Pacific 2019; 6 (1):2-6.
DOI: 10.5005/jp-journals-10040-1097
License: CC BY-NC 4.0
Published Online: 01-06-2019
Copyright Statement: Copyright © 2019; The Author(s).
Introduction: Chronic plantar fasciitis (PF) is the most common cause of foot complaints making up to 11–15% of the foot symptoms requiring professional care among adults. Also, it is a common problem that affects sport participants as well as inactive middle-aged individuals. The purpose of this study was to compare the effect of steroid and platelet-rich plasma (PRP) in chronic PF. The results were assessed by comparing American orthopedic foot and ankle scale (AOFAS) and visual analogue scale (VAS) before injection, 1, 2, and 6 months after injection in both groups comprising 25 patients in each group. Results: In our study of 50 patients, in steroid group-A, there is significant change in mean VAS from 6.28 ± 0.86 before follow-up injection to 2.8 ± 0.76 in first follow-up visit (1 month after injection) and to 2.92 ± 0.75 in second follow-up visit (2 months after 1st injection) and remained constant at 2.92 + 0.75 at third follow-up (6 months post 1st injection) and significant change in mean AOFAS from 67 ± 10 before injection to 85.76 ± 5.44 in first follow-up visit (1 month after injection) and to 84.16 + 5.94 in second follow-up visit (2 months after first injection) and deteriorated further to 83.92 + 5.84 at third follow-up (6 months after first injection). In 25 patients in group B, there is significant change in mean VAS from 5.8 ± 80.78 before follow-up injection to 1.96 ± 0.45 in first follow-up visit (1 month after injection) and to 1.96 ± 0.45 in second follow-up visit (2 months after first injection) and remained constant at 1.96 ± 0.45 at third follow-up (6 months post first injection) and significant change in AOFAS from 68.44 ± 17.78 before injection to 89.56 ± 0.91 in first follow-up visit (1 month after injection) and to 89.84 ± 0.55 in second follow-up visit (2 months after first injection) and improved further to 89.92 ± 0.40 at third follow-up (6 months after first injection). Conclusion: PRP injection is more effective than corticosteroid injection in the treatment of chronic PF in the long run.